Several randomized controlled trials have evaluated the effect of adjuvant treatment with interferon (IFN)-␣ of high-risk melanoma patients on recurrence-free interval and overall survival (OS) ( 1 -3 ). Pooled analyses of high-dose IFN trials in the United States and meta-analyses of high-, intermediate-, and low-dose IFN trials in both the United States and the Europe have demonstrated a
consistent and statistically significant effect of IFN treatment on recurrence-free interval but not on OS ( 1 , 2 ) . A recent metaanalysis based on individual patient data also found a statistically significant and consistent effect of IFN treatment on recurrence-free interval and a marginal, but statistically significant, effect of 3% on OS at 5 years ( 3 ). Optimal treatment dose or duration is still not known. These findings suggest the possible existence of a small subgroup of patients responding to IFN therapy. In view of the toxicity and costs of IFN therapy, it would therefore be of great benefit if this subgroup of patients could be identified.
A recent study by Gogas et al. ( 4 ) showed that the appearance of autoantibodies and clinical manifestations of autoimmunity in melanoma patients treated with adjuvant high-dose IFN was strongly associated with improved recurrence-free interval and OS. Also, the occurrence of autoimmune thyroid disease in patients receiving lowdose IFN has been reported to be associated with longer recurrencefree interval ( 5 ) . Although autoimmunity has been found to be associated with better prognosis in untreated melanoma patients as well, these two trials did not analyze the occurrence, and effects on prognosis, of autoimmunity in an observation group. Therefore, whether the appearance of autoimmunity was associated with the effectiveness of IFN treatment in melanoma patients could not be established.
The measurement of autoantibodies can be used as an index of immune response, which could be an indicator for effi cacy of treatment with adjuvant IFN. However, autoantibodies are also commonly detected in healthy persons and (untreated) cancer patients. Antinuclear antibody prevalence, for instance, ranges from 4% to 35% ( 6 -9 ) in healthy individuals, and frequencies of up to 40% have been reported in a series of patients with different types of cancer ( 10 ) . Thus, an observation group must be included in trials that seek to determine whether immune response is associated with response to IFN treatment.
We studied whether the occurrence of autoantibodies in melanoma patients receiving intermediate doses of IFN (IFN-␣ 2b) or no treatment was associated with response to treatment. Patients for this translational study were accrued in two large randomized trials: the European Organization for Research and Treatment of Cancer (EORTC) 18952 trial and the Nordic IFN trial. Both of these trials compared treatment with intermediate doses of IFN with observation ( 11 , 12 ) . Because the presence of autoantibodies varies over time, it was crucial to choose a statistical approach that took time to seroconversion (appearance of autoantibodies) into account. Therefore, we analyzed the relationship between the appearance of autoantibodies and recurrence-free interval using three Cox proportional regression m odels, in two of which the appearance of autoantibodies was treated as a time-dependent variable.
Patients and Methods

Patients
The EORTC 18952 study and the Nordic IFN trial were designed to evaluate efficacy and toxicity of intermediate doses of IFN in high-risk melanoma patients. For EORTC 18952, between 1996 and 2000, a total of 1388 patients who had been diagnosed with stage IIB melanoma were enrolled ( 11 ) . These patients had tumors with Breslow thickness 4 mm and greater and were lymph node negative (N0) or had undergone curative dissection of regional lymph nodes (either completion lymphadenectomy following positive sentinel node procedure [stage III, N1] or therapeutic lymph node dissection for palpable nodes [stage III, N2]). Patients were randomly assigned in relative proportions of 2:2:1 to 13 months of intermediate high-dose IFN, 25 months of intermediate low-dose IFN, or observation only, respectively. IFN-treated patients received an induction treatment of 4 weeks of 10 million units (MU) IFN, delivered 5 days a week. Induction was followed by either 10 MU IFN three times a week for 1 year or 5 MU IFN three times a week for 2 years, with all treatments delivered subcutaneously.
For the Nordic IFN trial, a total of 855 patients with stage IIB or III melanoma were enrolled between 1996 and 2004. Patients were randomly assigned in equal proportions to three treatment arms: observation only, induction treatment with 10 MU IFN 5 days a week for 4 weeks followed by 10 MU three times a week for 1 year (as in the 13-month IFN arm from the EORTC 18952), or induction treatment followed by 10 MU IFN three times a week for 2 years. All treatments were delivered by subcutaneous injection ( 12 ) . All available sera from 27 collaborating centers were collected, and autoantibody levels were determined centrally at the Laboratory for Experimental Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center in Rotterdam. The blood samples for this study were drawn at the same time points as for regular follow-up tests, that is, before treatment, at the end of the induction phase (1, 3, 6, 12, 16, 20 , and 24 months after the start of treatment), and at 30-and 36-month follow-up. Informed consent from patients for translational research in association with these trials for the purposes of identifi cation of prognostic factors was obtained.
CONTEXT AND CAVEATS
Prior knowledge
The appearance of autoantibodies in melanoma patients treated with interferon-␣ had been associated with improved recurrencefree survival and overall survival.
Study design
Cox regression models, each treating the patient ' s antibody status differently, were used to assess the association of seroconversion with recurrence-free survival.
Contribution
This study suggested that, contrary to previous reports, the appearance of autoantibodies is not strongly associated with improved outcome in melanoma patients treated with interferon.
Implications
Additional markers for selecting those melanoma patients who will benefit from interferon treatment will be needed.
Limitations
Only a subset of patients from the two clinical trials were included in this study, limiting the power to detect associations of a biomarker with outcome. ( 13 , 14 ) .
From the Editors
Statistical Analysis
Recurrence-free interval was the time from the date of random assignment until the first relapse or death without relapse, whichever occurred first; the follow-up of patients who did not relapse was censored at the latest visit or last contact. Time to appearance of autoantibodies was the time from the date of random assignment until the date a positive test was recorded; the follow-up of patients for whom no positive test was recorded was censored at the latest date of assessment of autoantibody status or date of relapse or last follow-up. The Kaplan -Meier method was used to estimate the survivor function distributions, and the log-rank test was used to test for differences between survival curves ( 15 ) . The association of the occurrence of observed autoimmunity with recurrence-free interval was assessed using three Cox models: one in which the appearance of autoantibodies was considered as a time-independent variable and two that considered autoimmunity as a time-dependent variable. In the three models, the prognostic importance of autoantibody status was adjusted for sex and the initial number of positive lymph nodes before random assignment, considered as an ordered categorical variable. Categories for the number of positive lymph nodes were 0, 1, 2 -4, and greater than or equal to 5 in the EORTC 18952 study, and 0, 1, 2 -3, and greater than or equal to 4 in the Nordic IFN study. In a Cox model in which autoantibody status was considered to be a time-independent variable ( Figure 1 , model 1) , the hazard ratio of the event intensity per time unit in autoantibody-positive patients vs autoantibody-negative patients according to the initial number of lymph nodes and sex was expressed as: HR = exp [ ␤ 1 × autoantibody status ( t ) + ␤ 2 × number of positive lymph nodes +
Autoantibody status ( t ) was set to 0 if all tests for autoantibodies were always negative or to 1 if an autoantibody test was at least once positive, whatever the moment of seroconversion (ie, autoantibody status [ t ] is time independent). Sex was entered as 0 for men and 1 for women. This model provides a biased estimate of the prognostic importance of autoantibody status because in patients who are alive and free of relapse for a longer time period, the possibility of seroconversion will be higher, whereas in those According to model 1, if one or more autoantibody tests are positive, the patient is considered autoantibody positive from baseline, regardless of when seroconversion occurred. This model is biased because patients who are alive and free of relapse for a longer period will have a greater chance to become autoantibody positive than those who had an early relapse. In model 2, the patient is considered autoantibody positive from the moment of seroconversion. This model tests the following hypothesis: the appearance of autoantibodies is indicative of treatment response, irrespective of the duration of seroconversion. Model 3 is the classical time-dependent Cox model. It uses the latest available information regarding autoantibody status. In contrast to model 2, it tests whether not only appearance but also duration of seroconversion is associated with prognosis. In case of a transient seroconversion in the autoantibody-positive group, the patient returns to the autoantibodynegative group upon testing negative. Model 3 assumes that from that time, the patient has the same prognosis as all other autoantibodynegative patients. Both models 2 and 3 correct for guarantee-time bias.
who have an early relapse, seroconversion will be less likely. This model therefore introduces guarantee-time bias ( 16 ) .
To determine whether autoantibody status assessed during the course of the study, before time t and before relapse, was associated with the subsequent outcome, two models in which antibody status was considered to be a time-dependent variable were used. In one Cox time-dependent model ( Figure 1 , model 2), for patients free of relapse just before a time point t , the hazard ratio was expressed as above, with autoantibody status ( t ) = 0 if autoantibody tests were always negative before time t and t = 1 from the moment the autoantibody status became positive, irrespective of whether it remained positive or returned to a negative status thereafter; thus, the variable is an indicator of the latest positive autoantibody status.
In model 3, for patients free of relapse just before a time point t , the hazard ratio was set as above, with autoantibody status ( t ) = 0 if the latest autoantibody status determined before or at time t was negative or t = 1 if the latest autoantibody status determined before or at time t was positive ( Figure 1 , model 3) . Thus, for purposes of risk assessment, the most recent value of autoantibody status at time t (determined at that time or earlier if not available at time t ) was used.
Both time-dependent models may provide different information because they discriminate differently for patients who switched from autoantibody-positive status back to autoantibodynegative status (transient seroconversion). Model 3 assumes that from the time the patient becomes autoantibody negative again, she or he has the same prognosis as all other autoantibodynegative patients. Model 2 considers patients once autoantibody positive as positive, regardless of any subsequent change to autoantibody-negative status.
Based on serial measurements of autoantibody status and the data for each patient on time of recurrence, the hazard ratio and its 95% confi dence interval (CI) were estimated. The Wald test (standardized coeffi cient) was used to determine the prognostic value of variables considered in the model. In addition, the landmark method, which also circumvents guarantee-time bias, was used to evaluate the association between autoantibody status based on serum samples available at 6 and 12 months after end of induction and subsequent recurrence-free interval. Because the samples were not all drawn at exactly these time points, a 60-day time interval window (±30 days around the theoretical date) was applied. To determine whether the autoantibody status (positive vs negative) has strong impact on the relapse-free survival, for example, the corresponding hazard ratio is 0.50, a total of 102 events were required to reach a statistical power of approximately 80% (twosided alpha = .05), considering that, in mean, over time, 30% of patients were in the autoantibody-positive status and 70% in the negative one. Statistical analyses using SAS 9.1 software (SAS Institute, Inc., Cary, NC) were performed at the EORTC Data Center. All statistical tests were two-sided.
Results
Patients
All available serum samples from patients accrued in both trials were collected for this study. Baseline autoantibody levels were determined in 187 and 356 patients in the EORTC 18952 and Nordic IFN trials, respectively. There were 62 patients (33%) in the EORTC 18952 study and 126 patients (35%) in Nordic IFN study who were positive at baseline for at least one of three autoantibodies and thus considered to have developed autoantibodies before treatment. No difference in recurrence-free interval between patients with or without preexisting autoantibodies was observed ( Supplementary Figure 1 , available online) . In the EORTC 18952 study, among the 125 patients who remained after exclusion of those who were autoantibody positive at baseline, 54 patients were randomly assigned to the 13-month IFN group, 48 to the 25-month IFN group, and 23 to the observation group. With a median follow-up of 4.2 years, recurrence-free interval did not differ by a statistically significant extent between treatment groups (overall P = .36) (13-month IFN vs observation, HR = 0.81, 95% CI = 0.46 to 1.40; 25-month IFN vs observation, HR = 0.66, 95% CI = 0.37 to 1.17). Median overall recurrence-free interval among all patients who were free of autoantibodies before treatment was 2.1 years. In the Nordic IFN trial, the 230 patients who did not test positive for one of the three antibodies were randomly assigned as follows: 70 patients to no-adjuvant treatment, 79 patients to IFN treatment for 13 months, and 81 patients to IFN treatment for 25 months. With a median follow-up of 6.8 years, no statistically significant difference in recurrence-free interval across treatment arms was observed (overall P = .43; 13-month IFN vs observation, HR = 0.76, 95% CI = 0.50 to 1.17; 25-month IFN vs observation, HR = 0.81, 95% CI = 0.53 to 1.24). Median recurrence-free interval for all 230 patients was 2.46 years.
Seroconversion
Seroconversion, the appearance of autoantibodies in patients who initially tested negative for all three autoantibodies, occurred in 43 (34%) of 125 and 73 (32%) of 230 patients in the EORTC 18952 and Nordic IFN trials, respectively. Frequencies of the three autoantibodies were summarized ( Supplementary Table 1 , available online). Antinuclear antibodies were the most prevalent in treated as well as untreated patients. Baseline characteristics according to treatment for patients in both trials who initially tested negative for the presence of autoantibodies were comparable with those of the total patient population from the EORTC 18952 ( 11 ) and Nordic IFN ( 12 ) trials ( Table 1 ). There were no differences in the crude rates of antibody appearance according to age, Breslow thickness, stage at random assignment, or number of positive lymph nodes. However, differences in the crude rates were seen according to treatment, sex, and the presence or absence of ulceration.
In the EORTC 18952 study, 37 (36%) of 102 patients in the IFN arms and six (26%) of 23 patients in the observation arm developed autoantibodies. The rate of seroconversion was higher in the IFN group compared with the observation arm, but the difference was not statistically signifi cant (HR for seroconversion = 1.64, 95% CI = 0.69 to 3.88; P = .26) ( Figure 2, A ) . In the Nordic IFN study, 63 (39%) of 160 patients in the IFN groups compared with 10 (14%) of 70 patients in the observation group developed autoantibodies (HR for seroconversion = 2.60, 95% CI = 1.33 to 5.07; P = .004) ( Figure 2, B ) .
Seroconversion rates for the IFN-treated patients were similar in both trials and higher in women than in men; percentages of patients in whom autoantibodies were detected were 31% and 35% of the men and 45% and 48% of the women in EORTC 18952 and Nordic IFN, respectively ( Table 1 ) . Also, in the observation group of the EORTC 18952 trial, a higher seroconversion rate for women was observed (46% in women vs 8% in men), but this group consisted of only 11 women and 12 men.
In both untreated and treated patients from the EORTC 18952 trial, patients with ulcerated tumors had higher seroconversion rates compared with patients with nonulcerated tumors. This was also true for the IFN-treated patients in the Nordic IFN trial. However, it is diffi cult to draw conclusions from these groups because the occurrence of seroconversion in patients with ulcerated tumors was not similar in the observation groups of the two trials, and ulceration status of the primary tumor was frequently unknown.
Autoantibodies were measured for a maximum of 3 years in the EORTC 18952 trial and 2 years in the Nordic IFN trial. In both trials, by 12 months, autoantibodies were detected in half of the patients, and the latest time point at which autoantibodies were initially detected was approximately 2 years.
Association of Seroconversion With Recurrence-Free Interval
In both trials, patients who became autoantibody positive during the study period had a statistically significantly better recurrence-free interval compared with those who remained autoantibody negative. In the EORTC 18952 trial, the 43 autoantibody-positive patients had a statistically significantly ( P < .001) lower relapse rate than the 82 autoantibody-negative patients (HR = 0.43, 95% CI = 0.27 to 0.71). In the Nordic IFN trial, 73 patients who became autoantibody positive during the course of the trial had a lower relapse rate than the 157 patients who remained autoantibody negative (HR = 0.51, 95% CI = 0.34 to 0.76; P < .001). Similar results were observed in IFN-treated patients only. In the EORTC 18952 study ( Figure 2, C ) , the 37 autoantibody-positive patients had statistically significantly better recurrence-free interval compared with the 65 autoantibodynegative patients (HR = 0.39, 95% CI = 0.23 to 0.69; P < .001). Kaplan -Meier estimates for the Nordic IFN trial ( Figure 2, D ) were comparable, showing a statistically significant benefit in recurrence-free interval ( P = .001) for the 63 autoantibody-positive patients compared with 97 autoantibody-negative patients (HR = 0.48, 95% CI = 0.30 to 0.75).
Using the Cox models, the prognostic importance of the autoantibody status was adjusted for sex and the number of positive lymph nodes because, unlike ulceration, these were independent prognostic factors for recurrence-free interval in this study. The association of sex with recurrence-free interval was more pronounced in the Nordic IFN trial. The results of the Cox model treating antibody status as a time-independent variable (model 1) and adjusting for sex and the number of positive lymph nodes were comparable with those obtained with the log-rank test (autoantibody-positive vs autoantibody-negative patients: HR = 0.41, 95% CI = 0.25 to 0.68 in the EORTC 18952 trial, and HR = 0.51, 95% CI = 0.34 to 0.76 in the Nordic IFN trial [ Table 2 ]). These results were similar when only patients in observation or treatment groups were considered.
However, these results were guarantee-time bias driven ( 15 , 16 ) because patients with a longer recurrence-free interval have a greater chance of developing autoantibodies, and, conversely, early relapses are more likely in autoantibody-negative patients because these patients relapse before autoantibodies develop or can be detected. Thus, survival estimates based on Kaplan -Meier curves are biased because they compare all patients who tested positive for autoantibodies with patients who never tested positive, regardless of when seroconversion occurred. To overcome the guaranteetime bias phenomenon, we used two Cox models that treated autoantibody status as a time-dependent variable ( Figure 1 ) : a model that used the latest positive autoantibody status and one that used latest autoantibody status regardless of whether it was positive or negative. When time to seroconversion was taken into account, using model 2, in which the latest positive autoantibody status was entered into the model, all hazard ratios for recurrence-free interval increased compared with model 1, and no statistically significant differences were seen between autoantibody-positive and autoantibody-negative patients. In this model as well, the number of positive lymph nodes was associated with recurrence-free interval. Model 3, which uses the latest autoantibody status, is the most appropriate one to correct for guarantee-time bias. According to this model, autoantibody-positive and autoantibody-negative patients did not differ by a statistically signifi cant extent in risk of recurrence. The association of the number of positive lymph nodes and sex with recurrence-free interval remained unchanged between the different Cox models, which is consistent with the idea that the subgroups analyzed are representative and similar.
Landmark analyses for IFN-treated patients at 6 and 12 months confi rmed the fi ndings from the models that treated autoantibody status as a time-dependent variable. In the Nordic IFN trial, 39 of 72 autoantibody-negative patients had a relapse at 6 months compared with 11 of the 29 autoantibody-positive patients (HR = 0.59, P = .12). At 12 months, results were similar; 26 of 55 autoantibody-negative patients vs 10 of 28 autoantibodypositive patients relapsed (HR = 0.65, P = .24). These analyses lacked statistical power because in a considerable number of patients, autoantibodies were not detected before 12 months, at which time some patients had relapsed. In the EORTC To explore the effects of using higher cutoff values to dichotomize autoantibody status, an analysis considering patients with a moderate test result for antibodies as negative was performed. Using the higher cutoff values, only 11 (6%) of 187 patients and 31 (9%) of 356 patients were initially strongly positive in the EORTC 18952 and Nordic IFN trials, respectively. After their exclusion, there remained 176 patients in EORTC 18952 and 325 patients in Nordic IFN. Among these patients, 145 and 227 patients received IFN treatment in EORTC 18952 and Nordic IFN, respectively. Although in the EORTC 18952 study, in the 18 (12%) IFN-treated patients with strong seroconversion, there was a trend toward better recurrence-free interval of marginal statistical signifi cance using models 2 and 3 (model 2: HR = 0.46, P = .07; and model 3: HR = 0.38, P = .06), this trend was not observed in the Nordic IFN trial, in which 42 (18%) strongly positive patients did not have statistically signifi cantly improved recurrence-free interval (model 2: HR = 0.79, P = .39; and model 3, HR = 0.83, P = .53; data not shown).
Discussion
Autoimmune conditions including thyroiditis and vitiligo induced by interleukin 2 and/or IFN therapy have been associated with an improved prognosis in melanoma patients ( 4 , 5 , 17 -19 ) . In this study, the appearance of autoantibodies was determined in IFNtreated patients, receiving intermediate doses of IFN-␣ 2b, as well as in untreated patients (observation arms of both trials). Autoantibodies were detected in both treated and untreated patients, but the frequency of autoantibody occurrence increased by 10 and 25 percentage points in the EORTC 18952 and Nordic IFN trials, respectively. The occurrence of autoantibodies in patients who were initially autoantibody negative was associated with a better outcome if a Cox model in which antibody status was time independent was used. However, using the models that treated antibody status as a time-dependent variable and thus corrected for guarantee-time bias, there was no strong association between seroconversion and recurrence-free interval. However, the most important prognostic factor in stage III melanoma patients, the number of positive lymph nodes ( 20 ) , was an independent prognostic factor in all models. Furthermore, the results pertaining to the association of seroconversion with recurrencefree interval were similar when only patients in the observation arm or treated patients were considered for analysis, indicating that the appearance of autoantibodies in melanoma patients is neither a prognostic nor a predictive serological marker for treatment outcome.
Our results are not in accordance with the study by Gogas et al. ( 4 ) , which demonstrated a statistically signifi cant improvement in both recurrence-free interval (HR = 0.12) and OS for patients with evidence of autoimmunity when correction for guarantee-time bias was applied. Furthermore, we observed that 33% of the patients in the EORTC 18952 study and 35% of those in the Nordic IFN trial had preexisting autoantibodies, which is in agreement with autoantibody prevalence reported in literature. Antinuclear antibodies are commonly detected in healthy persons, with reported prevalences ranging from 4% to 35% ( 6 -9 ), but prevalences up to 40% in cancer patients have been reported ( 10 ) . Furthermore, the reported prevalence of anticardiolipin and antithyroid antibodies in healthy control subjects ranges between 1% and 15% ( 6 , 21 -26 ) . Therefore, an autoantibody prevalence (defi ned by the presence of one of the three assayed antibodies) of 33% and 35%, reported for our studies at baseline, lies within the normal range. In contrast, the prevalence of 1.5% reported by Gogas et al. ( 4 ) is extraordinarily low. The difference between their study and our results cannot be explained by methodological differences because we used the same (validated) assays and titers described by Gogas et al. Moreover, our exploration of higher cutoff values did not change the overall results.
One could argue that patients with preexisting autoantibodies should not be excluded because this refl ects normal variability. We checked the association of preexisting autoantibodies with recurrence-free interval, and in both trials, no differences in recurrencefree interval were observed between initially autoantibody-positive and autoantibody-negative patients ( Supplementary Figure 1 , available online). Thus, autoantibody status before treatment is not a relevant factor in predicting recurrence-free interval.
An additional difference between our study and that of Gogas et al. was that we detected a higher seroconversion rate (36% and 39% in EORTC 18952 and Nordic IFN trials, respectively, compared with 26% in their study). Treatment duration may explain some of the difference because in both trials reported here, more seroconversions were observed in patients treated with IFN for 25 months than in those treated for 13 months, and the overall incidence of autoantibodies or autoimmune disorders in the study by Gogas et al. was 28% for the extended treatment group (1-year IFN) vs 24% in the induction group (4-week IFN) . The median time to seroconversion was only 3 months in the study by Gogas et al. compared with 6 -12 months in the trials reported here. A possible explanation for this difference could be the fact that the induction treatment differed: It consisted of 15 MU IFN delivered intravenously (5 days per week for 4 weeks) in the study by Gogas et al. compared with 10 MU IFN delivered subcutaneously (5 days per week for 4 weeks) in the EORTC 18952 and Nordic IFN trials.
The current study focused on the presence of autoantibodies as an indicator of autoimmune response in contrast to some other studies that also evaluated clinical manifestations of autoimmunity during IFN treatment. Autoimmune diseases are often preceded and/or accompanied by the occurrence of autoantibodies. From the 52 (26%) of the 200 IFN-treated patients with signs of autoimmunity in the study by Gogas et al., only three patients (2%) had clinical manifestations of autoimmunity (vitiligo) without autoantibodies. Therefore, using autoantibodies as an index of immune response seems reasonable.
Our study had some limitations. The EORTC and Nordic trials were originally not designed to determine whether serial serum autoantibody levels are prognostic and predictive markers. It turned out that the number of patients and events reported were suffi cient to assess the prognostic importance in the IFN-treated patients. However, in the observation groups, especially in the EORTC 18952 trial, the series was quite limited (23 patients), affecting the assessment of the prognostic value of autoantibody levels in this subgroup and, therefore, of its predictive value (differential effect in IFN and observation groups). The group of patients with prolonged recurrence-free interval is relatively small, suggesting that the treatment, if active at all, is only of benefi t in a minor patient population. Identifi cation of a potential biomarker is therefore only likely if this marker has a strong relationship with treatment benefi t.
The aim of this study was to assess the predictive value of autoantibody determination as a useful tool in selecting patients benefi ting from IFN treatment. The results of two similar randomized trials reported here do not suggest that the presence or appearance of autoantibodies is a strong prognostic factor in melanoma patients. Seroconversion was more frequently observed in patients receiving treatment, yet the time to seroconversion varied greatly. The fi ndings indicate that the assessment of autoimmune antibodies is not a useful tool in selecting patients who would benefi t from treatment with intermediate doses of IFN-␣ 2b.
